Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine XR vs Chlorpromazine in Acute Schizophrenia
NCT00882518Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2009
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of quetiapine (extended-release tablet, brand name: Bipresso) in schizophrenia (2 arms), sponsored by AstraZeneca. Primary endpoint: Change From Baseline of the Positive and Negative Syndrome Scale (PANSS) Total Score at 42 days. Started Apr 2009; status: completed.
02
Drugs
quetiapine (extended-release tablet, brand name: Bipresso)
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00882518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00882518.